XNASITOS
Market cap283mUSD
Jan 13, Last price
7.53USD
1D
-0.64%
1Q
-22.01%
IPO
-55.83%
Name
Iteos Therapeutics Inc
Chart & Performance
P/E
—
P/S
21.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
36.63%
Rev. gr., 5y
%
Revenues
13m
-95.29%
Net income
-113m
L
CFO
-104m
L-6.69%
Earnings
Mar 04, 2025
Profile
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
IPO date
Jul 24, 2020
Employees
125
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 12,595 -95.29% | 267,630 -22.38% | ||||
Cost of revenue | 164,594 | 142,119 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (151,999) | 125,511 | ||||
NOPBT Margin | 46.90% | |||||
Operating Taxes | 3,612 | 52,084 | ||||
Tax Rate | 41.50% | |||||
NOPAT | (155,611) | 73,427 | ||||
Net income | (112,642) -216.54% | 96,652 -54.95% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 1,113 | 925 | ||||
BB yield | -0.28% | -0.13% | ||||
| Debt | ||||||
Debt current | 2,502 | 836 | ||||
Long-term debt | 10,865 | 8,510 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 47,539 | 45,822 | ||||
Net debt | (619,088) | (722,041) | ||||
| Cash flow | ||||||
Cash from operating activities | (103,756) | (111,193) | ||||
CAPEX | (2,966) | (938) | ||||
Cash from investing activities | 72,658 | (446,062) | ||||
Cash from financing activities | 1,113 | 1,984 | ||||
FCF | (159,570) | 74,055 | ||||
| Balance | ||||||
Cash | 531,916 | 613,162 | ||||
Long term investments | 100,539 | 118,225 | ||||
Excess cash | 631,825 | 718,006 | ||||
Stockholders' equity | 111,429 | 227,667 | ||||
Invested Capital | 518,647 | 484,726 | ||||
ROIC | 15.98% | |||||
ROCE | 17.62% | |||||
| EV | ||||||
Common stock shares outstanding | 35,764 | 37,767 | ||||
Price | 10.95 -43.93% | 19.53 -58.05% | ||||
Market cap | 391,611 -46.91% | 737,580 -58.06% | ||||
EV | (227,477) | 15,539 | ||||
EBITDA | (151,101) | 126,314 | ||||
EV/EBITDA | 1.51 | 0.12 | ||||
Interest | 19,149 | |||||
Interest/NOPBT | 15.26% | |||||